4Laboratory Medicine Practice Guidelines Use of Tumor Markers in Clinical Practice:QualityRequirements Edited by Catharine M[J].Sturgeon and Eleftherios Diamandis.
5Loi S,Haydon AM,Shapiro J,et al.Towards evidence-based use of serum tumour marker requests:an audit of use in a tertiary hospital[J].Intern Med J,2004,34(6):545-550.
6Roddam AW,Price CP,Allen NE,et al.Assessing the clinical impact of prostate-specific antigen assay variability and nonequimolarity:a simulation study based on the population of the United Kingdom[J].Clin Chem,2004,50(6):1012-1016.
7Sturgeon C,Ellis A,Al-Sadie R.Annual Review for 2007.www.ukneqas.org.uk(Accessed 28th July,2008).
8White P.Annual Review for PSA.http://www.immqas.org.uk/(Accessed 28th July,2008).
9Kort SA,Martens F,Vanpoucke H,et al.Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation[J].Clin Chem,2006,52(9):1568-1574.
10Stephan C,Klaas M,Muller C,et al.Interchangeability of measurements of total and free prostatespecific antigen in serum with 5 frequently used assay combinations:an update[J].Clin Chem,2006,52(28):59-64.
